NEW YORK (GenomeWeb News) – Celera said today that the US Food and Drug Administration has granted marketing clearance for the firm’s ViroSeq HIV-1 Genotyping System Software v2.8.
The Alameda, Calif.-based firm’s HIV-1 Genotyping System detects mutations in the HIV-1 viral genome that confer resistance. It is used by physicians in monitoring and treating HIV-1 infections.
The newest version of the software includes the resistance algorithm for two new anti-HIV drugs, Intelence (etravirine) and Prezista (darunavir). It also includes an update of the resistance algorithm for all currently available protease and reverse transcriptase inhibitors, said Celera.
The ViroSeq system is manufactured by Celera and distributed by Abbott Laboratories.